明らかに変異が乳腺組織におけるフィールドがん化を引き起こすメカニズム
PubMedで要約を見る
まとめ
この要約は機械生成です。健康な組織は 3つの保護層を通して 豊富な腫瘍変異にもかかわらず 腫瘍を予防します これらのメカニズムはほとんどの変異細胞を排除しますが,一部は拡大し,潜在的にフィールドがん化につながる可能性があります.
科学分野
- 細胞生物学
- 癌の研究
- 発達生物学
背景
- 腫瘍性突然変異は健康な組織では一般的ですが,腫瘍を引き起こすことは稀です.
- 腫瘍の形成を防ぐ防御メカニズムはよく理解されていません.
研究 の 目的
- マウスの乳腺組織における腫瘍性変異に対する保護機構を調査する.
- 細胞がどのように突然変異を起こすか 腫瘍の発生に繋がるかを理解する
主な方法
- 野生型および Brca1-/-;Trp53-/- マウスの乳腺組織における細胞運命を追跡するための系統追跡.
- 乳管内の細胞動態を研究するためのクローン分析
主要な成果
- 乳腺管には 自己再生する幹細胞と 短命の子孫が含まれており,ほとんどの新しい変異を排除することで 最初の保護層を提供します.
- エストラサイクル中の組織改造は 第二の保護層を提供し ほとんどの変異クローンを排除するが,一部を拡大させる.
- ダクト幾何学は第三の保護層を課し,クローンの拡大を抑制し,生き残ったクローンのフィールド癌化につながります.
結論
- 腫瘍性変異の細胞を排除するために,乳組織には複数の保護層が存在します.
- ほとんどの突然変異は 解消されますが 少数の突然変異は 広がり 細胞の突然変異が広がり 組織が癌に 誘発されます
- これらのメカニズムを理解することは 癌の予防と治療の戦略に不可欠です
関連する概念動画
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

